Cencora (COR) Stock Forecast & Price Target $330.77 -7.71 (-2.28%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$330.56 -0.20 (-0.06%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Cencora - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 18 Analyst RatingsSell0Hold4Buy14 Based on 18 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for COR. Consensus Price Target $366.4410.78% Upside According to the 18 analysts' twelve-month price targets for Cencora, the average price target is $366.44. The highest price target for COR is $400.00, while the lowest price target for COR is $310.00. The average price target represents a forecasted upside of 10.78% from the current price of $330.77. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for COR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COR Analyst Ratings Over TimeTypeCurrent Forecast10/25/25 to 10/25/261 Month Ago9/25/25 to 9/25/263 Months Ago7/27/25 to 7/27/261 Year Ago10/25/24 to 10/25/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy14 Buy rating(s)14 Buy rating(s)13 Buy rating(s)9 Buy rating(s)Hold4 Hold rating(s)4 Hold rating(s)4 Hold rating(s)3 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$366.44$369.19$364.93$324.91Forecasted Upside10.78% Upside20.21% Upside17.18% Upside-2.43% DownsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy COR Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History COR Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Cencora Stock vs. The CompetitionTypeCencoraHealthcare CompaniesBroader MarketConsensus Rating Score 2.78 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside10.78% Upside1,400.11% Upside16.92% UpsideNews Sentiment RatingPositive NewsSee Recent COR NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/25/2024 - 10/25/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/22/2026 Robert W. Baird3 of 5 starsDavid Rodgers3 of 5 starsBoost TargetOutperform$373.00 ➝ $375.00+10.15%10/20/2026 Argus3 of 5 starsDavid Toung4 of 5 starsBoost TargetBuy$340.00 ➝ $380.00+11.74%10/16/2026 UBS Group4 of 5 starsKevin Caliendo3 of 5 starsLower TargetBuy$430.00 ➝ $400.00+16.81%10/7/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankingsMichael ChernySubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$380.00 ➝ $388.00+21.42%10/6/2026 Weiss RatingsSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeBuy (B-) ➝ Buy (B)9/8/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access to unlock brokerage rankingsRyan HalstedSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingSector Perform$330.00+0.91%8/11/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsStephen BaxterSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$331.00 ➝ $395.00+21.85%8/7/2026 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankingsErin WrightSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$342.00 ➝ $346.00+7.00%8/7/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsLisa GillSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$382.00 ➝ $390.00+20.86%8/6/2026 EvercoreSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingOutperform$330.00 ➝ $350.00+10.18% Get the Latest News and Ratings for COR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter. 8/6/2026 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankingsDaniel GrosslightSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy7/21/2026 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankingsMichael FunkSubscribe to MarketBeat All Access to unlock analyst rankingsBoost Target$285.00 ➝ $310.00-4.73%6/10/2026 BarclaysSubscribe to MarketBeat All Access to unlock brokerage rankingsGlen SantangeloSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOverweight$425.00 ➝ $350.00+25.38%4/28/2026 William BlairSubscribe to MarketBeat All Access to unlock brokerage rankingsMax SmockSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageMarket Perform1/22/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsBrian TanquilutSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeUnderperform ➝ Buy11/25/2025 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$371.00 ➝ $389.00+19.52%11/10/2025 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankingsCharles RhyeeSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$350.00 ➝ $400.00+10.23%11/6/2025 MizuhoSubscribe to MarketBeat All Access to unlock brokerage rankingsSteven ValiquetteSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$340.00 ➝ $380.00+7.70%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:33 PM ET. Should I Buy Cencora Stock? COR Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com. Cencora Bull Case Here are some ways that investors could benefit from investing in Cencora, Inc.: Cencora, Inc. recently announced a definitive agreement to acquire the remaining 96% stake in American Oncology Network for approximately $2.4 billion, a strategic move that adds about 350 physicians to its network and strengthens its support for community oncology practices, potentially expanding its provider network and oncology-related revenue opportunities. Analyst sentiment remains positive with recent price target increases, such as Robert W. Baird raising its target to $375.00 and Argus lifting its target to $380.00, both maintaining buy or outperform ratings, which signals confidence in the company's growth prospects and suggests potential upside from the current stock price of $330.77. The company demonstrated strong financial performance in its most recent quarterly earnings report, beating analysts' consensus estimates with earnings per share of $4.48 compared to the expected $4.35, while also reporting revenue of $84.75 billion, which exceeded the consensus estimate of $84.31 billion and represented a 5.1% year-over-year increase. Short interest in Cencora, Inc. has been declining over recent months, with the number of shares shorted dropping to 3,919,355 as of September 30, 2026, down from 5,872,438 in July 2026, indicating that fewer investors are betting against the stock and suggesting a shift in market sentiment toward the company. Institutional investors continue to show interest in the stock, with 26 exchange-traded funds adding to their Cencora holdings in mid-October 2026, and several hedge funds, such as Nisa Investment Advisors LLC, increasing their positions in the third quarter, which reflects ongoing institutional demand and confidence in the company's long-term value. Cencora Bear Case Investors should be bearish about investing in Cencora, Inc. for these reasons: The $2.4 billion acquisition of American Oncology Network, while strategically attractive, introduces risks related to the purchase price, financing, and integration costs, and investors will need to assess the company's ability to generate sufficient returns from the expanded physician platform to justify the investment. Some analysts have taken a more cautious stance, with UBS lowering its price target to $400, which, although still above the current trading level, creates a counterpoint to the more bullish revisions from other firms and suggests potential limitations in the stock's near-term upside. Insider selling activity has been notable, with EVP Elizabeth Campbell selling 11,300 shares in August 2026 and CEO Robert P. Mauch selling 5,096 shares in January 2026, which may signal that company executives are taking advantage of higher stock prices to reduce their personal holdings. The company's debt-to-equity ratio stands at 3.53, indicating a relatively high level of leverage, which could limit its financial flexibility and increase its vulnerability to economic downturns or rising interest rates, potentially affecting its ability to fund future acquisitions or operations. Cencora, Inc. experienced a significant drop in its stock price following its May 2026 earnings report, hitting a 52-week low of $244.82, which suggests that the market may be skeptical about the company's ability to sustain its growth trajectory or manage its costs effectively in the face of competitive pressures. COR Forecast - Frequently Asked Questions What is Cencora's forecast for 2026? According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $366.44, with a high forecast of $400.00 and a low forecast of $310.00. Should I buy or sell Cencora stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares. Does Cencora's stock price have much upside? According to analysts, Cencora's stock has a predicted upside of 10.78% based on their 12-month stock forecasts. Has Cencora been upgraded by Wall Street analysts recently? Over the previous 90 days, Cencora's stock had 2 upgrades by analysts. What analysts cover Cencora? Cencora has been rated by research analysts at Argus, Citigroup, Evercore, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Cencora more than its competitors? Analysts like Cencora more than other "healthcare" companies. The consensus rating for Cencora is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how COR compares to other companies. Stock Forecasts and Research Tools Related Companies Cardinal Health Stock Forecast Elevance Health Stock Forecast McKesson Stock Forecast Henry Schein Stock Forecast AdaptHealth Stock Forecast Cosmos Health Stock Forecast 111 Stock Forecast Wellgistics Health Stock Forecast Ridgetech Stock Forecast Hong Kong Pharma Digital Technology Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Cencora RecommendationsRobert W. BairdArgusUBS GroupLeerink PartnersWeiss RatingsRoyal Bank Of CanadaWells Fargo & CompanyWall Street ZenMorgan StanleyJPMorgan Chase & Co.EvercoreCitigroupBank of AmericaBarclaysWilliam Blair MarketBeat monitors more than a dozen sources for Cencora analyst ratings, with the most recent rating issued on 10/22/2026. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cencora, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cencora With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.